Secukinumab demonstrates significantly lower immunogenicity potential compared with ixekizumab and adalimumab

Background: Secukinumab (SEC), a fully human monoclonal antibody (mAb) that selectively neutralizes IL-17A, has significant efficacy in the treatment of moderate to severe plaque psoriasis (Pso) and psoriatic arthritis (PsA), demonstrating a rapid onset of action and sustained responses up to 5 years with a favorable safety profile and 0.4% immunogenicity in the Pso phase 3 program. SEC has previously demonstrated lower potential for immunogenicity compared with other mAbs used to treat Pso and PsA in in vitro assays.